RxSight, Inc. (RXST) Stock Forecast & Price Target

RxSight, Inc. (RXST) has an ST Score of 42.0 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate RXST a Hold, with a price target of $7.31 (+54.5% vs the current price). Our ST Score grades it C (42.0/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B, Profitability C, Financial Strength B+, Momentum D-, Growth C-, Forecast B.

RxSight, Inc. (RXST) earns a valuation grade of B, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

RxSight, Inc. (RXST) earns a growth grade of C-, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

RxSight, Inc. (RXST) earns a profitability grade of C, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

RxSight, Inc. (RXST) earns a financial strength grade of B+, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for RxSight, Inc. (RXST) is $7.31 from 12 analysts, which is +54.5% versus the recent price of $4.73.

RxSight, Inc. (RXST) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.